Nasal sprays to stave off viruses days at a time? J&J’s newest biotech partner draws $140M for 'proactive' approach
Vaccines. Antibodies. Antivirals. The Covid-19 pandemic has given the world a crash course on the key medical tools that can protect humans from viruses. But one startup believes there’s plenty of room for another new option.
Blue-chip investors are pouring support into the company, Leyden Labs, with a $140 million Series B to back its broad “protection at the gate” approach.
The name of the game at Leyden is intranasal sprays that can be administered mucosally — including compounds developed in-house and formulations of existing experimental drugs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.